Hepatitis B Control
Country Profile 2022

World Health Organization
Western Pacific Region
Hepatitis B Control
Country Profile 2022
<table>
<thead>
<tr>
<th>Country Profiles</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Samoa</td>
<td>3</td>
</tr>
<tr>
<td>Australia</td>
<td>4</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>5</td>
</tr>
<tr>
<td>Cambodia</td>
<td>6</td>
</tr>
<tr>
<td>China</td>
<td>7</td>
</tr>
<tr>
<td>China, Hong Kong SAR</td>
<td>8</td>
</tr>
<tr>
<td>China, Macao SAR</td>
<td>9</td>
</tr>
<tr>
<td>Cook Islands</td>
<td>10</td>
</tr>
<tr>
<td>Fiji</td>
<td>11</td>
</tr>
<tr>
<td>French Polynesia</td>
<td>12</td>
</tr>
<tr>
<td>Guam</td>
<td>13</td>
</tr>
<tr>
<td>Japan</td>
<td>14</td>
</tr>
<tr>
<td>Kiribati</td>
<td>15</td>
</tr>
<tr>
<td>Lao People’s Democratic Republic</td>
<td>16</td>
</tr>
<tr>
<td>Malaysia</td>
<td>17</td>
</tr>
<tr>
<td>Marshall Islands</td>
<td>18</td>
</tr>
<tr>
<td>Micronesia (Federated States of)</td>
<td>19</td>
</tr>
<tr>
<td>Mongolia</td>
<td>20</td>
</tr>
<tr>
<td>Nauru</td>
<td>21</td>
</tr>
<tr>
<td>New Caledonia</td>
<td>22</td>
</tr>
<tr>
<td>New Zealand</td>
<td>23</td>
</tr>
<tr>
<td>Niue</td>
<td>24</td>
</tr>
<tr>
<td>Northern Mariana Islands, Commonwealth of the</td>
<td>25</td>
</tr>
<tr>
<td>Palau</td>
<td>26</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>27</td>
</tr>
<tr>
<td>Philippines</td>
<td>28</td>
</tr>
<tr>
<td>Republic of Korea</td>
<td>29</td>
</tr>
<tr>
<td>Samoa</td>
<td>30</td>
</tr>
<tr>
<td>Singapore</td>
<td>31</td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>32</td>
</tr>
<tr>
<td>Tokelau</td>
<td>33</td>
</tr>
<tr>
<td>Tonga</td>
<td>34</td>
</tr>
<tr>
<td>Tuvalu</td>
<td>35</td>
</tr>
<tr>
<td>Vanuatu</td>
<td>36</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>37</td>
</tr>
<tr>
<td>Wallis and Futuna</td>
<td>38</td>
</tr>
</tbody>
</table>
Regional Progress
Hepatitis B vaccination coverage, 1990 – 2022

Source: WHO and UNICEF Joint Reporting Form on Immunization
Regional coverage is based on calculated average among all countries, whether they reported coverage or not
Regional Progress as of December 2022

Status of the 2022 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO Regional Office for the Western Pacific 2023. All rights reserved
AMERICAN SAMOA

Demographics

<table>
<thead>
<tr>
<th>Total population (2022)</th>
<th>44,273</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2022)</td>
<td>765</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>760</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>90%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1986-1987
- HepB birth dose introduced: 1991
- Current schedule: 0, 1 month, 12 months
- HepB3 type: Monovalent

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
--- | --- | --- | --- | --- | --- | --- | --- |
1990 | National | 3-4 years | 95 | not reported | 82% | not reported | Mahoney Pac Hth Dialog 1996 |
1995 | National | 7-8 years | 432 | 75% | 91% | not reported | Bialek ISVHLG P351 2006 |
1996 | National | 7-8 years | 435 | not reported | 87% | not reported | Mahoney Pac Hth Dialog 1996 |
2016 | National | 24-35 months | 1180 | 97% | 82% | 85% | MMWR May 25, 2018 / 67(20);579-584 |

Status of verifying prevalence targets

- Verification started: February 2013
- Decision: <1% in children
- Decision date: October 2014

Vaccination coverage surveys

| Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
--- | --- | --- | --- | --- | --- | --- | --- |
1990 | National | 3-4 years | 95 | not reported | 82% | not reported | Mahoney Pac Hth Dialog 1996 |
1995 | National | 7-8 years | 432 | 75% | 91% | not reported | Bialek ISVHLG P351 2006 |
1996 | National | 7-8 years | 435 | not reported | 87% | not reported | Mahoney Pac Hth Dialog 1996 |
2016 | National | 24-35 months | 1180 | 97% | 82% | 85% | MMWR May 25, 2018 / 67(20);579-584 |

Hepatitis B serological surveys

| Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes |
--- | --- | --- | --- | --- | --- | --- |
1991 | Tutuila | 3-4 years | Community based | 93 | 2.2% | Mahoney JID 2009 |
1995 | National | 7-8 years | Community based | 432 | 0.5% | Bialek ISVHLG P351 2006 |
2011 | National | 6 years | School based | 562 | 0.2% | Govt American Samoa 2012 |

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**Demographics**

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2022)</td>
<td>26,177,413</td>
</tr>
<tr>
<td>Births (2022)</td>
<td>300,246</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>299,523</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>86%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

<table>
<thead>
<tr>
<th>Vaccine Introduction</th>
<th>Year</th>
<th>Current Schedule</th>
<th>HepB3 Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3 introduced nationwide</td>
<td>2000</td>
<td>0, 2 months, 4 months, 6 months</td>
<td>DTP-Hib-HepB-IPV</td>
</tr>
<tr>
<td>HepB birth dose introduced</td>
<td>2000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WHO verification**

- **Status of verifying prevalence targets**
  - Verification started: June 2012
  - Decision: <1% in children
  - Decision date: December 2012

**Neonatal deliveries**

- Total population (2022): 26,177,413
- Births (2022): 300,246
- Surviving infants (2022): 299,523
- Urban population (2020): 86%

**Hepatitis B vaccination coverage**

- Timely HepB BD
- Any HepB BD
- HepB3

**2022 Districts by coverage categories**

- <50%
- 50%-79%
- 80%-89%
- 90%-94%
- >94%

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>12 months</td>
<td>280,874</td>
<td>not reported</td>
<td>94%</td>
<td>92%</td>
<td>From National Health Insurance covering 99% of population</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>National</td>
<td>1-9 years</td>
<td>Hospital based</td>
<td>249</td>
<td>0.4% (0.0% - 2.2%)</td>
<td>Gidding Vaccine 2007</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
BRUNEI DARUSSALAM

Demographics

- Total population (2022): 449,002
- Births (2022): 6,058
- Surviving infants (2022): 6,009
- Urban population (2020): 80%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-Hib-HepB-IPV

WHO verification

- Status of verifying prevalence targets
  - Verification started: March 2013
  - Decision: <1% in children
  - Decision date: June 2013

Neonatal deliveries

- Women aged 15-49:
  - Skilled birth attendant: 0%
  - In health facility: 0%
- Women aged 15-19:
  - Skilled birth attendant: 0%
  - In health facility: 0%

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
---|---|---|---|---|---|---|---
2011 | National | 8-9 years | School based | 4,513 | 0.09% | |

Vaccination Coverage (%)

- Timely HepB BD
- Any HepB BD
- HepB3

2022 Districts by coverage categories

- Districts: <50% <50%-79% 80%-89% 90%-94% >94%

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
---|---|---|---|---|---|---
2011 | National | 8-9 years | School based | 4,513 | 0.09% | MoH Brunei 2012

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

Total population (2022): 16,767,842
Births (2022): 318,335
Surviving infants (2022): 312,448
Urban population (2020): 24%

Hepatitis B vaccine

HepB3 introduced nationwide: 2005
HepB birth dose introduced: 2005
Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
HepB3 type: DTWP-Hib-HepB

WHO verification

Status of verifying prevalence targets
Verification started: January 2018
Decision: <1% in children
Decision date: June 2018

Neonatal deliveries

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2005 National 12-23 months 1517 not reported not reported 78% DHS Survey
2009 National 12-23 months 1068 61% not reported 56% Cambodia Socio-Economic Survey 2009 (confirmation method only by card)
2010 National 12-23 months 1614 73% 84% 84% DHS Survey: HepB BD 73%, HepB3 85%, DTP3 85% by 12 months
2014 National 12-23 months 1460 83% 84% 84% DHS Survey: HepB BD 83%, HepB3 82%, DTP3 82% by 12 months

Vaccination coverage surveys

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2001 Kg Chhnang 9-17 months Hospital based 900 2.7% Report MoH/PATR/AIHI
2006 National 5 years Community based 1,558 3.5% (2.4% - 4.8%) Soeung AMTH 2009
2011 Urban, Rural, Remote 4-5 years Community based 2,429 0.3%, 1.4%, 3.5% Mao Vaccine 2013
2017 National 5-6 years Community based 2,520 0.6% (0.3% - 1.0%) Cambodia MOH 2017 preliminary data
2017 National 5-7 years Cross-sectional survey 2,520 0.56% Ork Vaccine 2019

Hepatitis B serological surveys

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes
2001 Kg Chhnang 9-17 months Hospital based 900 2.7% Report MoH/PATR/AIHI
2006 National 5 years Community based 1,558 3.5% (2.4% - 4.8%) Soeung AMTH 2009
2011 Urban, Rural, Remote 4-5 years Community based 2,429 0.3%, 1.4%, 3.5% Mao Vaccine 2013
2017 National 5-6 years Community based 2,520 0.6% (0.3% - 1.0%) Cambodia MOH 2017 preliminary data
2017 National 5-7 years Cross-sectional survey 2,520 0.56% Ork Vaccine 2019

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
CHINA

Demographics
Total population (2022) 1 425 887 337
Births (2022) 10 757 794
Surviving infants (2022) 10 703 232
Urban population (2020) 61%

Hepatitis B vaccine
HepB3 introduced nationwide 1992
HepB birth dose introduced 1992
Current schedule 0, 1 month, 6 months
HepB3 type Monovalent

WHO verification
Status of verifying prevalence targets
Verification started: February 2012
Decision: <1% in children
Decision date: June 2012

Vaccination surveys
Survey year Location Ages enrolled Sampling base Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2004 National 12-23 months Community based 171 188 not reported 85% not reported The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months
2006 National 1 year Community based 3636 93% 83% not reported Liang JID 2009; 2005 birth cohort
2008 National 12-23 months Community based 9762 not reported 93% 91% Analysis Report of National Health Services Survey in China

Hepatitis B serological surveys
Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes
2006 National 1-4 years Community based 16 376 1.0% (0.8% - 1.2%) Liang JID 2009
2006 National 5 years Community based 2215 1.1% (0.4% - 1.8%) Liang JID 2009
2006 National 6 years Community based 2356 0.9% (0.4% - 1.5%) Liang JID 2009
2012 National 1-4 years Community based 5474 0.5% (0.3% - 0.7%) Yonghao International Journal of Infectious Diseases 2015
2012 National 5-9 years Community based 4407 0.7% (0.5% - 1.0%) Yonghao International Journal of Infectious Diseases 2015
2012 National 10-14 years Community based 3326 1.2% (0.8% - 1.6%) Yonghao International Journal of Infectious Diseases 2015
2014 National 1-4 years Community based 12 681 0.3% (0.2% - 0.5%) Cui FQ Emerging Infectious Diseases 2017
2014 National 5-14 years Community based 9738 0.9% (0.7% - 1.3%) Cui FQ Emerging Infectious Diseases 2017
2014 National 15-29 years Community based 9294 4.4% (3.8% - 5.1%) Cui FQ Emerging Infectious Diseases 2017

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
HONG KONG SAR (CHINA)

### Demographics

- Total population (2022): 7,488,865
- Births (2022): 41,923
- Surviving infants (2022): 41,874
- Urban population (2020): 100%

### Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

### WHO verification

- Verification started: February 2011
- Decision: <1% in children
- Decision date: July 2011

### Neonatal deliveries

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>2-5 years</td>
<td>6248</td>
<td>not reported</td>
<td>≥99.5%</td>
<td>&gt;99.8%</td>
<td>MoH Hong Kong 2011</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>2-5 years</td>
<td>not reported</td>
<td>&gt;95.0%</td>
<td>&gt;95.0%</td>
<td>&gt;95.0%</td>
<td>WHO-UNICEF Joint Reporting Form (data for 2017)</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>1-4 years</td>
<td>Laboratory based</td>
<td>196</td>
<td>1%</td>
<td>MoH Hong Kong 2011</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-15 years</td>
<td>School based</td>
<td>1913</td>
<td>0.8% (0.4% - 1.2%)</td>
<td>MoH Hong Kong 2011</td>
</tr>
</tbody>
</table>

### 2022 Districts by coverage categories

<table>
<thead>
<tr>
<th>% District</th>
<th>HepB3</th>
<th>Timely HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50%-79%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80%-94%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥95%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Abbreviations

- DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Sources

- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
MACAO SAR (CHINA)

Demographics

- Total population (2022): 695,168
- Births (2022): 6,957
- Surviving infants (2022): 6,944
- Urban population (2020): 100%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1984
- HepB birth dose introduced: 1989
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

Hepatitis B vaccination coverage

- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent
- Survey year: 2022
- Location: Districts by coverage categories*

WHO verification

- Status of verifying prevalence targets
  - Verification started: April 2008
  - Decision: <1% in children
  - Decision date: August 2008

Neonatal deliveries

- Total population: 695,168
- Births: 6,957
- Surviving infants: 6,944
- Urban population: 100%

Hepatitis B serological surveys

- Survey year: 2003
- Location: National
- Ages enrolled: 6-9 years
- Sampling base: School based
- Sample size: 437
- HBsAg prevalence (95%CI): 0% (0% - 0.7%)

Sources:
- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

Abbreviations:
- DTP3: 3rd dose of Diptheria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2022)</td>
<td>17,011</td>
</tr>
<tr>
<td>Births (2022)</td>
<td>275</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>274</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>75%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB

### WHO verification

- Verification started: January 2013
- Decision: <1% in children
- Decision date: October 2013

### Neonatal deliveries

- Skilled birth attendant

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>269</td>
<td>0%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

- 0-100

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>School based</td>
<td>269</td>
<td>0%</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

### Abbreviations

- DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Sources

- Total population was from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
FIJI

Demographics

- Total population (2022): 929,766
- Births (2022): 17,821
- Surviving infants (2022): 17,538
- Urban population (2020): 59%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTwP-Hib-HepB

Neonatal deliveries

- Total population (2022): 929,766
- Births (2022): 17,821
- Surviving infants (2022): 17,538
- Urban population (2020): 59%

Hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>National</td>
<td>12-23 months</td>
<td>not reported</td>
<td>not reported</td>
<td>94%</td>
<td>92%</td>
<td>Fiji National EPI Survey</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>630</td>
<td>not reported</td>
<td>92%</td>
<td>83%</td>
<td>Fiji Immunization Coverage Survey Report</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>15-26 months</td>
<td>1200</td>
<td>86%</td>
<td>99%</td>
<td>99%</td>
<td>Fiji National Immunisation Coverage Survey</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>not reported</td>
<td>not reported</td>
<td>not reported</td>
<td>not reported</td>
<td>91%</td>
<td>WHO-UNICEF Joint Reporting Form (Data for 2014)</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>285</td>
<td>0.7%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2008</td>
<td>Sub-national</td>
<td>6 months-5 years</td>
<td>Community based</td>
<td>428</td>
<td>0%</td>
<td>WHO:RS/2009/GE/23(JPN)</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization HepB3 coverage at national and district level are inconsistent due to different data sources used by Fiji.
### Demographics

<table>
<thead>
<tr>
<th>Total population (2022)</th>
<th>306,279</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2022)</td>
<td>3,844</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>3,825</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>6.4%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- **HepB3 introduced nationwide**: 1992
- **HepB birth dose introduced**: 1992
- **Current schedule**: 0, 2 months, 10 months
- **HepB3 type**: DTP-Hib-HepB-IPV

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: February 2016
  - Decision: <1% in children
  - Decision date: September 2016

### Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Austral Island</td>
<td>0-11 months</td>
<td>957</td>
<td>2.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In health facility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>Any HepB BD</th>
<th>HepB3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>40%</td>
<td>70%</td>
<td>60%</td>
</tr>
<tr>
<td>2019</td>
<td>40%</td>
<td>70%</td>
<td>60%</td>
</tr>
<tr>
<td>2020</td>
<td>40%</td>
<td>70%</td>
<td>60%</td>
</tr>
<tr>
<td>2021</td>
<td>40%</td>
<td>70%</td>
<td>60%</td>
</tr>
<tr>
<td>2022</td>
<td>40%</td>
<td>70%</td>
<td>60%</td>
</tr>
</tbody>
</table>

### 2022 Districts by coverage categories

<table>
<thead>
<tr>
<th>District</th>
<th>HepB3</th>
<th>Timely HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Austral Island</td>
<td>0-11 months</td>
<td>Community based</td>
<td>957</td>
<td>2.1%</td>
<td>B Trans R Soc Trop 1990</td>
</tr>
<tr>
<td>2013-2014</td>
<td>National</td>
<td>6-7 years</td>
<td>School based</td>
<td>1196</td>
<td>0.0% (0.0%-0.5%)</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
GUAM

Demographics

- Total population (2022): 171,774
- Births (2022): 2,817
- Surviving infants (2022): 2,793
- Urban population (2020): 95%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1-2 months, 6-18 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: October 2015
  - Decision: <1% in children
  - Decision date: June 2016

Neonatal deliveries

- Women aged 15-49: 0%
- Women aged 15-19: 0%
- In health facility: 0%

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2022 Districts by coverage categories

Survey year
Location
Ages enrolled
Sample size
HepB BD %
HepB3 %
DTP3 %
Reference/Notes

Survey year
Location
Ages enrolled
Sampling base
Sample size
HBsAg prevalence (95%CI)
Reference/Notes

2015
National
6 years
School based
1484
0.0%
Guam DoH & Social Services 2015

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
Demographics

- Total population (2022): 123,951,692
- Births (2022): 814,705
- Surviving infants (2022): 813,535
- Urban population (2020): 92%

Hepatitis B vaccine

- HepB3 introduced nationwide: October 2016
- HepB birth dose introduced: if born to HBsAg+ mothers
- Current schedule: 2 months, 3 months, 7 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

- Total population (2022): 123,951,692
- Births (2022): 814,705
- Surviving infants (2022): 813,535
- Urban population (2020): 92%

Hepatitis B vaccination coverage

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>Okinawa</td>
<td>1-4 years</td>
<td>School based</td>
<td>1529</td>
<td>0.1%</td>
<td></td>
<td>Hayashi Int J Epi 1990</td>
</tr>
<tr>
<td>1995-1996</td>
<td>National</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>107,879</td>
<td>0.4% (0.4% - 0.5%)</td>
<td>Furusyo AMTM 1998</td>
<td></td>
</tr>
<tr>
<td>1995-2000</td>
<td>National</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>582,415</td>
<td>0.23% (0.22% - 0.24%)</td>
<td>Tanaka Intervirol 2004</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Iwate prefecture</td>
<td>5-9 years</td>
<td>School based</td>
<td>17,363</td>
<td>0.0% (0.00%-0.04%)</td>
<td>Tanaka Intervirol 2011</td>
<td></td>
</tr>
<tr>
<td>2005-2010</td>
<td>National</td>
<td>4-15 years</td>
<td>Serum reference bank</td>
<td>3000</td>
<td>0.17% (0.0-0.41)</td>
<td>Kiyohara T Vaccine 2015</td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>Okinawa</td>
<td>1-4 years</td>
<td>School based</td>
<td>1529</td>
<td>0.1%</td>
<td>Hayashi Int J Epi 1990</td>
</tr>
<tr>
<td>1995-1996</td>
<td>National</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>107,879</td>
<td>0.4% (0.4% - 0.5%)</td>
<td>Furusyo AMTM 1998</td>
</tr>
<tr>
<td>1995-2000</td>
<td>National</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>582,415</td>
<td>0.23% (0.22% - 0.24%)</td>
<td>Tanaka Intervirol 2004</td>
</tr>
<tr>
<td>2009</td>
<td>Iwate prefecture</td>
<td>5-9 years</td>
<td>School based</td>
<td>17,363</td>
<td>0.0% (0.00%-0.04%)</td>
<td>Tanaka Intervirol 2011</td>
</tr>
<tr>
<td>2005-2010</td>
<td>National</td>
<td>4-15 years</td>
<td>Serum reference bank</td>
<td>3000</td>
<td>0.17% (0.0-0.41)</td>
<td>Kiyohara T Vaccine 2015</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**Demographics**

- Total population (2022): 131,232
- Births (2022): 3,512
- Surviving infants (2022): 3,400
- Urban population (2020): 57%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1995
- HepB birth dose introduced: 1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTwp-Hib-HepB

**WHO verification**

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Neonatal deliveries**

- Women aged 15-49: Skilled birth attendant
- Women aged 15-19: In health facility

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>48-59 months</td>
<td>181</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>36-47 months</td>
<td>200</td>
<td>not reported</td>
<td>not reported</td>
<td>42%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>24-35 months</td>
<td>202</td>
<td>not reported</td>
<td>not reported</td>
<td>50%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-23 months</td>
<td>233</td>
<td>not reported</td>
<td>61%</td>
<td>61%</td>
<td>DHS Survey: HepB3 58%, DTP3 58% by 12 months</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>156</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>1249</td>
<td>3.3% (2.4% - 4.6%)</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
LAO PEOPLE'S DEMOCRATIC REPUBLIC

Demographics
- Total population (2022): 7,529,475
- Births (2022): 161,682
- Surviving infants (2022): 157,386
- Urban population (2020): 36%

Hepatitis B vaccine

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>828</td>
<td>not reported</td>
<td>not reported</td>
<td>41%</td>
<td>Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months</td>
</tr>
<tr>
<td>2011-2012</td>
<td>National</td>
<td>12-23 months</td>
<td>2141</td>
<td>37%</td>
<td>56%</td>
<td>56%</td>
<td>Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>5981</td>
<td>72%</td>
<td>81%</td>
<td>81%</td>
<td>National Immunization Survey</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>965</td>
<td>1.7% (0.8% - 2.6%)</td>
<td>Xeuatvongsa PloS ONE 2014</td>
</tr>
</tbody>
</table>

WHO verification
- Status of verifying prevalence targets: pending
- Verification started: n.a.
- Decision: n.a.
- Decision date: n.a.

Verification started: pending
Decision: n.a.
Decision date: n.a.

Neonatal deliveries

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>828</td>
<td>not reported</td>
<td></td>
</tr>
<tr>
<td>2011-2012</td>
<td>National</td>
<td>12-23 months</td>
<td>2141</td>
<td>1.7% (0.8% - 2.6%)</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>5981</td>
<td>1.7% (0.8% - 2.6%)</td>
<td></td>
</tr>
</tbody>
</table>

Vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>828</td>
<td>not reported</td>
<td>not reported</td>
<td>41%</td>
<td>Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months</td>
</tr>
<tr>
<td>2011-2012</td>
<td>National</td>
<td>12-23 months</td>
<td>2141</td>
<td>37%</td>
<td>56%</td>
<td>56%</td>
<td>Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>5981</td>
<td>72%</td>
<td>81%</td>
<td>81%</td>
<td>National Immunization Survey</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Material and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
MALAYSIA

Demographics

- Total population (2022): 33,938,221
- Births (2022): 509,232
- Surviving infants (2022): 506,637
- Urban population (2020): 78%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 2 months, 3 months, 5 months, 18 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: March 2011
  - Decision: <1% in children
  - Decision date: July 2011

Neonatal deliveries

- Skilled birth attendant

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2022 Districts by coverage categories

- <50%
- 50%-79%
- 80%-89%
- 90%-94%
- >94%

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
1997-2007 | National | 6-9 years | School based | 193,717 | 0.40% | MoH Malaysia 2011
2003 | National | 7 years | School based | 12,269 | 0.40% | Ng Med Microb Imm 2005
2007 | National | 7-9 years | Community based | 1735 | 0.30% | MoH Malaysia 2008
2009 | National | 9 years | School based | 2938 | 0.2% (0% - 0.3%) | MoH Malaysia 2011
2009 | National | 10 years | School based | 3265 | 0.4% (0.2% - 0.6%) | MoH Malaysia 2011

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
Demographics

- Total population (2022): 41,569
- Births (2022): 770
- Surviving infants (2022): 753
- Urban population (2020): 70%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1990s
- HepB birth dose introduced: 1998
- Current schedule: 0, 2 months, 4 months, 6 months, 12 months, 4-6 year
- HepB3 type: DTP-HepB-IPV

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

- Total population (2022): 41,569
- Births (2022): 770
- Surviving infants (2022): 753
- Urban population (2020): 70%
- HepB3 introduced nationwide: 1990s
- HepB birth dose introduced: 1998
- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

Hepatitis B vaccination coverage

- Survey year: 2018-2022
- Location: National
- Ages enrolled
  - 0-24 months: Sample size 115, HepB3 % 86%
  - 24-35 months: Sample size 1312, HepB3 % 76%
  - 12-23 months: Sample size 249, HepB3 % 32%
- Vaccination coverage (%): 80%, 80%, 80%

2022 Districts by coverage categories

- Coverage categories: <50%, 50%-79%, 80%-89%, 90%-94%, >94%
- Districts: Timely HepB BD, Any HepB BD, HepB3

Vaccination coverage surveys

- Survey year: 2006-2016
- Location: National, Majuro, Ebeye
- Ages enrolled
  - 0-24 months: Sample size 115, HepB % 86%
  - 4-6 years: Sample size 1148, HepB % 80%
- HepB3 %: 86%, 80%
- DTP3 %: 65%, 48%

Hepatitis B serological surveys

- Survey year: 2006-2016
- Location: Majuro, Ebeye, National
- Ages enrolled
  - 5-9 years: Sample size 331, HBsAg prevalence (95%CI): 1.8% (0.4% - 3.3%)
  - 5-6 years: Sample size 1148, HBsAg prevalence (95%CI): 1.2% (0.6% - 1.9%)
- Reference/Notes:
  - RMI Community Survey 2006: confirmation method by card only
  - Bialek Ped Infect Dis 2010
  - DHS Survey 2007: DTP3 by 12 months
  - Bialek PID 2010
  - MMWR May 25, 2018 / 67(20);579-584

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**FEDERATED STATES OF MICRONESIA**

### Demographics
- **Total population (2022):** 114,164
- **Births (2022):** 2,368
- **Surviving infants (2022):** 2,328
- **Urban population (2020):** 21%

### Hepatitis B Vaccine
- **HepB3 introduced nationwide:** 1988
- **HepB birth dose introduced:** 1988
- **Current schedule:** 0, 2 months, 4 months, 6 months
- **HepB3 type:** DTaP-HepB-IPV

### WHO Verification
- **Status of verifying prevalence targets:**
  - **Verification started:** October 2017
  - **Decision:** <1% in children
  - **Decision date:** March 2018

### Neonatal deliveries

### Vaccination coverage surveys
- **Survey year:** 1989
  - **Location:** National
  - **Ages enrolled:** 2 years
  - **Sample size:** 16,391
  - **HepB BD %:** not reported
  - **HepB3 %:** 84%
  - **DTP3 %:** not reported
  - **Reference/Notes:** Manea PH Reports 1992
- **Survey year:** 1992
  - **Location:** Chuuk
  - **Ages enrolled:** 2 years
  - **Sample size:** 544
  - **HepB BD %:** not reported
  - **HepB3 %:** 40%
  - **DTP3 %:** not reported
  - **Reference/Notes:** Mahoney Pac Hth Dialog 1996
- **Survey year:** 1994
  - **Location:** Pohnpei
  - **Ages enrolled:** 3-4 years
  - **Sample size:** 364
  - **HepB BD %:** not reported
  - **HepB3 %:** 82%
  - **DTP3 %:** not reported
  - **Reference/Notes:** Mahoney Pac Hth Dialog 1996
- **Survey year:** 2000
  - **Location:** Chuuk
  - **Ages enrolled:** 2-6 years
  - **Sample size:** 365
  - **HepB BD %:** 50%
  - **HepB3 %:** 87%
  - **DTP3 %:** not reported
  - **Reference/Notes:** Bialek ISVHLD P351 2006
- **Survey year:** 2005
  - **Location:** Pohnpei
  - **Ages enrolled:** 2-9 years
  - **Sample size:** 478
  - **HepB BD %:** 87%
  - **HepB3 %:** 90%
  - **DTP3 %:** not reported
  - **Reference/Notes:** Bialek Ped Infect Dis 2010
- **Survey year:** 2005
  - **Location:** National
  - **Ages enrolled:** 2-9 years
  - **Sample size:** 432
  - **HepB BD %:** 75%
  - **HepB3 %:** 91%
  - **DTP3 %:** not reported
  - **Reference/Notes:** Bialek ISVHLD P351 2006
- **Survey year:** 2016
  - **Location:** Chuuk
  - **Ages enrolled:** 24-25 months
  - **Sample size:** 1,218
  - **HepB BD %:** 54%
  - **HepB3 %:** 78%
  - **DTP3 %:** 72%
  - **Reference/Notes:** MMWR May 25, 2018 / 67(20);579-584

### Hepatitis B serological surveys
- **Survey year:** 2005
  - **Location:** Chuuk
  - **Ages enrolled:** 2-6 years
  - **Sampling base:** Hospital based
  - **Sample size:** 362
  - **HBsAg prevalence (95%CI):** 2.5%
  - **Reference/Notes:** Bialek PID 2010
- **Survey year:** 2005
  - **Location:** Pohnpei
  - **Ages enrolled:** 2-6 years
  - **Sampling base:** Hospital based
  - **Sample size:** 478
  - **HBsAg prevalence (95%CI):** 1.5%
  - **Reference/Notes:** Bialek PID 2010
- **Survey year:** 2016
  - **Location:** National
  - **Ages enrolled:** 5-6 years
  - **Sampling base:** School based
  - **Sample size:** 2,106
  - **HBsAg prevalence (95%CI):** 0.3% (0.1% - 0.5%)
  - **Reference/Notes:** 2017 MoH Federated States of Micronesia

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
**Demographics**

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2022)</td>
<td>3,398,366</td>
</tr>
<tr>
<td>Births (2022)</td>
<td>69,481</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>68,948</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>67%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB3 BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>National</td>
<td>12-23 months</td>
<td>1,255</td>
<td>not reported</td>
<td>not reported</td>
<td>89%</td>
<td>Mongolia, Child and Development survey-2000 (MICS-2), 2001</td>
</tr>
<tr>
<td>2004</td>
<td>National</td>
<td>4-6 years</td>
<td>5,894</td>
<td>95%</td>
<td>73%</td>
<td>not reported</td>
<td>MoH Mongolia 2011</td>
</tr>
<tr>
<td>2004</td>
<td>National</td>
<td>8 years</td>
<td>1,145</td>
<td>65%</td>
<td>60%</td>
<td>not reported</td>
<td>Davaalkham J Epid 2007</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>944</td>
<td>97%</td>
<td>not reported</td>
<td>93%</td>
<td>Mongolia Child and Development 2005 Survey (MICS-3): DTP3-92% by 12M</td>
</tr>
<tr>
<td>2010</td>
<td>National</td>
<td>12-23 months</td>
<td>1,180</td>
<td>99%</td>
<td>98%</td>
<td>98%</td>
<td>MICS : HepB BD 96.7% by 12M; DPT3 92.1% by 12M</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>24-35 months</td>
<td>1,236</td>
<td>97%</td>
<td>96%</td>
<td>96%</td>
<td>Mongolia Social Indicator Sample Survey: HepB BD 93.1%, HepB3 92.5%, DTP3 92.5% by 12M</td>
</tr>
</tbody>
</table>

**WHO verification**

- **Status of verifying prevalence targets**
  - Verification started: April 2012
  - Decision: <1% in children
  - Decision date: July 2012

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>National</td>
<td>7-12 years</td>
<td>School based</td>
<td>1,145</td>
<td>5.2%</td>
<td>Davaalkham PI 2007</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>4 years</td>
<td>Community based</td>
<td>5,894</td>
<td>0.5%</td>
<td>MoH Mongolia 2011</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

- **Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- **Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
### NAURU

#### Demographics
- Total population (2022): 12,668
- Births (2022): 341
- Surviving infants (2022): 336
- Urban population (2020): 100%

#### Hepatitis B vaccine
- HepB3 introduced nationwide: 1983
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTwP-Hib-HepB

#### WHO verification
- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

#### Neonatal deliveries
- Skilled birth attendant: 100%

#### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 2022 Districts by coverage categories

#### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:**
- DTP3: 3rd dose of Diptheria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

**Sources:**
- Total population was from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked Reference/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
NEW CALEDONIA

### Demographics
- Total population (2022): 289,950
- Births (2022): 4,095
- Surviving infants (2022): 4,062
- Urban population (2020): 72%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 2 months, 11 months
- HepB3 type: DTaP-Hib-HepB-IPV

### WHO verification
- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Neonatal deliveries

### Hepatitis B vaccination coverage

#### 2022 Districts by coverage categories*

### Vaccination coverage surveys

### Hepatitis B serological surveys

### Abbreviations:
- DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Sources:
- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

### Notes:
- HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
NEW ZEALAND

Demographics

- Total population (2022): 5,185,288
- Births (2022): 64,103
- Surviving infants (2022): 63,911
- Urban population (2020): 87%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: If born to HBsAg+ mothers
- Current schedule: 6 weeks, 3 months, 5 months
- HepB3 type: DTaP-Hib-HepB-IPV

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>12 months</td>
<td>1563</td>
<td>72%</td>
<td>82%</td>
<td>85%</td>
<td>MoH; 87% HepB3 by 2 years</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: April 2012
  - Decision: <1% in children
  - Decision date: September 2012

Neonatal deliveries

- Skilled birth attendant
- In health facility

Hepatitis B vaccination coverage

2022 Districts by coverage categories*

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>North Islands</td>
<td>6 years</td>
<td>Health facility</td>
<td>466</td>
<td>0.2% (0.0% - 1.2%)</td>
<td>Weir R. MoH New Zealand 2009</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diptheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
## Demographics

- **Total population (2022):** 1,934
- **Births (2022):** 27
- **Surviving infants (2022):** 27
- **Urban population (2020):** 47%

## Hepatitis B vaccine

- **HepB3 introduced nationwide:** 1986
- **HepB birth dose introduced:** Yes, introduction year unknown
- **Current schedule:** 0, 6 weeks, 3 months, 5 months
- **HepB3 type:** DTaP-Hib-HepB-IPV

## WHO verification

- **Verification started:** November 2015
- **Decision:** <1% in children
- **Decision date:** February 2017

### Status of verifying prevalence targets

- **HepB3 introduced nationwide:** 1986
- **HepB birth dose introduced:** Yes, introduction year unknown
- **Current schedule:** 0, 6 weeks, 3 months, 5 months
- **HepB3 type:** DTaP-Hib-HepB-IPV

## Neonatal deliveries

- **Total population (2022):** 1,934
- **Births (2022):** 27
- **Surviving infants (2022):** 27
- **Urban population (2020):** 47%

## Vaccination coverage surveys

### Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2015 | National | 5-12 years | School based | 183 | 0.0% | | Patel Vaccine 2016

## Neonatal deliveries

### Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
2015 | National | 5-12 years | School based | 183 | 0.0% | | Patel Vaccine 2016

### Abbreviations:
- DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Sources:
- Total population was from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
NORTHERN MARIANA ISLANDS, COMMONWEALTH OF THE

Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2022)</td>
<td>49,551</td>
</tr>
<tr>
<td>Births (2022)</td>
<td>604</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>601</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>88%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 6 months
- HepB3 type: DTaP-HepB-IPV

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>National</td>
<td>3-4 years</td>
<td>200</td>
<td>not reported</td>
<td>94%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>19-35 months</td>
<td>295</td>
<td>100%</td>
<td>94%</td>
<td>not reported</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>24-35 months</td>
<td>1,140</td>
<td>98%</td>
<td>62%</td>
<td>60%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: December 2015
  - Decision: <1% in children
  - Decision date: April 2017

Neonatal deliveries

- Total population (2022): 49,551
- Births (2022): 604
- Surviving infants (2022): 601
- Urban population (2020): 88%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>Saipan</td>
<td>3-4 years</td>
<td>Health facility</td>
<td>200</td>
<td>0.5%</td>
<td></td>
<td>Durand Pac Hth Dial 1996</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>6 years</td>
<td>School based</td>
<td>804</td>
<td>0.0%</td>
<td></td>
<td>CNMI Healthcare Corp. 2015</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>Saipan</td>
<td>3-4 years</td>
<td>Health facility</td>
<td>200</td>
<td>0.5%</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>6 years</td>
<td>School based</td>
<td>804</td>
<td>0.0%</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Palau

**Demographics**

- Total population (2022): 18,055
- Births (2022): 270
- Surviving infants (2022): 267
- Urban population (2020): 100%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 6 months
- HepB3 type: DTaP-HepB-IPV

**WHO verification**

- Status of verifying prevalence targets:
  - Verification started: January 2013
  - Decision: <1% in children
  - Decision date: May 2013

**Neonatal deliveries**

- Total population (2022): 18,055
- Births (2022): 270
- Surviving infants (2022): 267
- Urban population (2020): 100%

**Hepatitis B vaccination coverage**

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 6 months
- HepB3 type: DTaP-HepB-IPV

**Verification started:** January 2013
**Decision:** <1% in children
**Decision date:** May 2013

**Status of verifying prevalence targets**

**Survey year** | **Location** | **Ages enrolled** | **Sample size** | **HepB BD %** | **HepB3 %** | **DTP3 %** | **Reference/Notes**
--- | --- | --- | --- | --- | --- | --- | ---
2003 | National | 10-11 years | 192 | 100% | 85% | not reported | Bialek ISVHLD P351 2006
2016 | National | 24-35 months | 259 | 97% | 93% | 95% | MMWR May 25, 2018 / 67(20);579-584

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>10-11 years</td>
<td>Community based</td>
<td>192</td>
<td>0%</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2008</td>
<td>Main Island</td>
<td>5-7 years</td>
<td>School based</td>
<td>143</td>
<td>0%</td>
<td>MoH Palau 2013</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

**Sources:**
- Total population was from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
PAPUA NEW GUINEA

Demographics

- Total population (2022): 10,142,619
- Births (2022): 254,718
- Surviving infants (2022): 247,322
- Urban population (2020): 13%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: ~2003
- Current schedule: 0, 1 month, 2 months, 3 months
- HepB3 type: DTwP-Hib-HepB

Neonatal deliveries

- Total population (2022): 10,142,619
- Births (2022): 254,718
- Surviving infants (2022): 247,322
- Urban population (2020): 13%

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2005-2006 | National | 12-23 months | 2137 | not reported | 65% | 67% | National Immunization Coverage Survey

Hepatitis B serological surveys

- Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
1989-1990 | Port Moresby | 3-5 months | Hospital Based | 31 | 13% | Nemba ATPaed. 1993
2012-2013 | National | 4-6 years | Community based | 2109 | 2.3% | Kitau ASTMH 2015

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
PHILIPPINES

Demographics

- Total population (2022): 115,559,009
- Births (2022): 2,499,081
- Surviving infants (2022): 2,450,775
- Urban population (2020): 47%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998-1999</td>
<td>National</td>
<td>12-23 months</td>
<td>1474</td>
<td>not reported</td>
<td>not reported</td>
<td>81%</td>
<td>DHS Survey: DTP3 79% by 12 months</td>
</tr>
<tr>
<td>2000</td>
<td>National</td>
<td>12-23 months</td>
<td>2227</td>
<td>not reported</td>
<td>32%</td>
<td>80%</td>
<td>Philippines, Maternal and Child Health Survey 2000</td>
</tr>
<tr>
<td>2002</td>
<td>National</td>
<td>12-23 months</td>
<td>1885</td>
<td>not reported</td>
<td>not reported</td>
<td>81%</td>
<td>Philippines, Maternal and Child Health Survey 2002</td>
</tr>
<tr>
<td>2003</td>
<td>National</td>
<td>12-23 months</td>
<td>1348</td>
<td>not reported</td>
<td>not reported</td>
<td>79%</td>
<td>DHS Survey: DTP3 75% by 12 months</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>12-23 months</td>
<td>1286</td>
<td>not reported</td>
<td>80%</td>
<td>86%</td>
<td>DHS Survey (NDHS) 2008: by 12 months (HepB3 76%, DTP3 83%)</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>12-23 months</td>
<td>1397</td>
<td>not reported</td>
<td>78%</td>
<td>86%</td>
<td>DHS Survey, 2013: by 12 months (HepB3 74%, DTP3 85%)</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>National</td>
<td>5-7 years</td>
<td>Household survey</td>
<td>2,178</td>
<td>0.8%</td>
<td>Minta PubMed 2021</td>
</tr>
</tbody>
</table>

Status of verifying prevalence targets

- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total population (2022): 51,815,810
- Births (2022): 285,686
- Surviving infants (2022): 285,127
- Urban population (2020): 82%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1983
- HepB birth dose introduced: 1983
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>National</td>
<td>0-6 years</td>
<td>1026</td>
<td>100%</td>
<td>93%</td>
<td>95%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>19-35 months</td>
<td>not reported</td>
<td>not reported</td>
<td>99%</td>
<td>99%</td>
<td>2009 Korea National Immunization Survey (Confirmation method NA)</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>0-3 years</td>
<td>7040</td>
<td>99%</td>
<td>98%</td>
<td>93%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>10-14 years</td>
<td>Community based</td>
<td>594</td>
<td>0.2% (0.0% - 0.6%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>4-6 years</td>
<td>Hospital based</td>
<td>2920</td>
<td>0.2% (0.0% - 0.4%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>10-18 years</td>
<td>Community based</td>
<td>510</td>
<td>0.1%</td>
<td>KNHANES 2014</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
- Verification started: January 2008
- Decision: <1% in children
- Decision date: June 2008

Neonatal deliveries

- Proportion of deliveries with skilled birth attendant:
  - Women aged 15-49: 100%
  - Women aged 15-19: 80%
  - In health facility: 60%

Vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2022 Districts by coverage categories

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**Demographics**

- **Total population (2022):** 222,382
- **Births (2022):** 6,024
- **Surviving infants (2022):** 5,944
- **Urban population (2020):** 18%

**Hepatitis B vaccine**

- **HepB3 introduced nationwide:** 1990
- **HepB birth dose introduced:** Yes, introduction year unknown
- **Current schedule:** 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type:** DTwP-HiB-HepB

**WHO verification**

- **Status of verifying prevalence targets:**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Neonatal deliveries**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>12-24 months</td>
<td>321</td>
<td>70%</td>
<td>not reported</td>
<td>not reported</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>18-29 months</td>
<td>321</td>
<td>not reported</td>
<td>not reported</td>
<td>38%</td>
<td>DHS Survey: 37% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>48-59 months</td>
<td>559</td>
<td>75%</td>
<td>45%</td>
<td>45%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>36-47 months</td>
<td>605</td>
<td>81%</td>
<td>50%</td>
<td>50%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>24-35 months</td>
<td>680</td>
<td>82%</td>
<td>54%</td>
<td>54%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>674</td>
<td>84%</td>
<td>64%</td>
<td>64%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>18-29 months</td>
<td>666</td>
<td>83%</td>
<td>64%</td>
<td>64%</td>
<td>DHS Survey; by 18 months 83% HepB, 63% HepB3 and 63% DTP3</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccination coverage**

![Graph showing vaccination coverage](image)

**2022 Districts by coverage categories**

![District coverage chart](image)

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>National</td>
<td>5-6 years</td>
<td>School based</td>
<td>1776</td>
<td>0.11%</td>
<td>MoH Samoa 2015</td>
</tr>
</tbody>
</table>

**Abbreviations:**

- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours
- HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage

**Sources:**

- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

---

**SAMOA**
SINGAPORE

Demographics
- Total population (2022): 5,975,689
- Births (2022): 42,333
- Surviving infants (2022): 42,273
- Urban population (2020): 100%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: 1987
- Current schedule: 0, 1 month, 5-6 months
- HepB3 type: Monovalent

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>2 years</td>
<td>31,778</td>
<td>not reported</td>
<td>94%-96%</td>
<td>97%</td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998-1999</td>
<td>National</td>
<td>0-4 years</td>
<td>not reported</td>
<td>229</td>
<td>0%</td>
<td>Epi News Bull SNG 2000</td>
</tr>
<tr>
<td>2008-2010</td>
<td>Two public hospitals</td>
<td>1-17 years</td>
<td>Hospital based</td>
<td>1200</td>
<td>0.3% (0.1%-0.9%)</td>
<td>Ang J Med Virol 2013</td>
</tr>
</tbody>
</table>

WHO verification
- Status of verifying prevalence targets
  - Verification started: April 2015
  - Decision: <1% in children
  - Decision date: October 2015

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
### Demographics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>724,273</td>
<td>21,262</td>
<td>20,960</td>
<td>23%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- **HepB3 introduced nationwide**: 1990
- **HepB birth dose introduced**: ~2005
- **Current schedule**: 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type**: DTwP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>48-59 months</td>
<td>477</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>36-47 months</td>
<td>515</td>
<td>not reported</td>
<td>not reported</td>
<td>81%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>24-35 months</td>
<td>533</td>
<td>not reported</td>
<td>not reported</td>
<td>80%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>12-23 months</td>
<td>535</td>
<td>not reported</td>
<td>not reported</td>
<td>88%</td>
<td>DHS Survey (87% DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Timely HepB BD</td>
<td>30%</td>
<td>70%</td>
<td>2%</td>
<td>13%</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2019</td>
<td>Any HepB BD</td>
<td>30%</td>
<td>70%</td>
<td>2%</td>
<td>13%</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2020</td>
<td>HepB3</td>
<td>30%</td>
<td>70%</td>
<td>2%</td>
<td>13%</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2021</td>
<td>Timely HepB BD</td>
<td>30%</td>
<td>70%</td>
<td>2%</td>
<td>13%</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2022</td>
<td>HepB3</td>
<td>30%</td>
<td>70%</td>
<td>2%</td>
<td>13%</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Guadalcanal Islands</td>
<td>0-9 years</td>
<td>Hospital based</td>
<td>115</td>
<td>13%</td>
<td>Furusyo Am J Trop 1999</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>6-7 years</td>
<td>School based</td>
<td>1169</td>
<td>3.1% (2.0% - 4.9%)</td>
<td>Breakwell Vaccine 2020</td>
</tr>
</tbody>
</table>

### Abbreviations

- **DTP3**: 3rd dose of Diphteria, Tetanus and Pertusis vaccine
- **HepB3**: at least 3 doses of hepatitis B vaccine
- **HBsAg**: hepatitis B surface antigen
- **SBA**: Skilled Birth Attendant
- **Timely HepB BD**: birth dose within 24 hours

### Sources

- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision.
- Urban Population was derived from World Bank.
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data).
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
**Demographics**

- **Total population (2022)**: 1,871
- **Births (2022)**: 35
- **Surviving infants (2022)**: 35
- **Urban population (2020)**: 0%

**Hepatitis B vaccine**

- **HepB3 introduced nationwide**: 1990
- **HepB birth dose introduced**: 1990
- **Current schedule**: 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type**: DTwP-Hib-HepB

**WHO verification**

- **Status of verifying prevalence targets**: May 2015
  - Verification started: May 2015
  - Decision: <1% in children
  - Decision date: June 2016

**Neonatal deliveries**

- **TOKELAU**
  - **Total population (2022)**: 1,871
  - **Births (2022)**: 35
  - **Surviving infants (2022)**: 35
  - **Urban population (2020)**: 0%

- **HepB3 introduced nationwide**: 1990
- **HepB birth dose introduced**: 1990
- **Current schedule**: 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type**: DTwP-Hib-HepB

**Survey year** | **Location** | **Ages enrolled** | **Sample size** | **HepB BD %** | **HepB3 %** | **DTP3 %** | **Reference/Notes**
---|---|---|---|---|---|---|---
2014 | National | 6-12 years | School based | 171 | 0.0% | | Patel Vaccine 2016

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>National</td>
<td>6-12 years</td>
<td>School based</td>
<td>171</td>
<td>0.0%</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
### Demographics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2022)</td>
<td>106,858</td>
</tr>
<tr>
<td>Births (2022)</td>
<td>2,456</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>2,436</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>24%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTwP·Hib·HepB

### WHO verification

- Status of verifying prevalence targets
- Verification started: May 2011
- Decision: <2% in children
- Decision date: January 2012

### Neatinal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>12-23 months</td>
<td>114</td>
<td>not reported</td>
<td>94%</td>
<td>96%</td>
<td>Evaluation of Immunization Program of the Kingdom of Tonga</td>
</tr>
<tr>
<td>2005</td>
<td>Tongatapu hospital</td>
<td>6-59 months</td>
<td>445</td>
<td>92%</td>
<td>98%</td>
<td>98%</td>
<td>Danielsson Vaccine 2009</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>48-59 months</td>
<td>302</td>
<td>not reported</td>
<td>61%</td>
<td>61%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>36-47 months</td>
<td>334</td>
<td>not reported</td>
<td>59%</td>
<td>59%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>24-35 months</td>
<td>383</td>
<td>not reported</td>
<td>60%</td>
<td>60%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>12-23 months</td>
<td>307</td>
<td>not reported</td>
<td>66%</td>
<td>66%</td>
<td>DHS Survey (65% HepB3 and 65% DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccination coverage

- **2018 to 2022**
- Proportion of deliveries
- Skilled birth attendant: Women aged 15-49
- In health facility: Women aged 15-19

### 2022 Districts by coverage categories

- **<50%**
- **50%-79%**
- **80%-89%**
- **90%-94%**
- **>94%**

### Abbreviations

- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
TUVALU

Demographics
Total population (2022) 11,312
Births (2022) 265
Surviving infants (2022) 261
Urban population (2020) 62%

Hepatitis B vaccine
HepB3 introduced nationwide Yes, introduction year unknown
HepB birth dose introduced Yes, introduction year unknown
Current schedule 0, 6 weeks, 10 weeks, 14 weeks
HepB3 type DTp-Hib-HepB

WHO verification
Status of verifying prevalence targets
Verification started: pending
Decision: n.a.
Decision date: n.a.

Neonatal deliveries

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2007 National 48-59 months 75 not reported not reported 59% DHS Survey (DTP3 by 18 months)
2007 National 36-47 months 84 not reported not reported 57% DHS Survey (DTP3 by 18 months)
2007 National 24-35 months 89 not reported not reported 60% DHS Survey (DTP3 by 18 months)
2007 National 18-29 months 80 not reported not reported 62% DHS Survey (60% DTP3 by 18 months)

Vaccination coverage surveys

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2018 National 15-49 years 1,000 90% 94% 97% WHO report
2019 National 15-49 years 1,000 90% 94% 97% WHO report
2020 National 15-49 years 1,000 90% 94% 97% WHO report
2021 National 15-49 years 1,000 90% 94% 97% WHO report
2022 National 15-49 years 1,000 90% 94% 97% WHO report

Hepatitis B serological surveys

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes
1976 Fanafuti 10-19 years Community based 181 11% Gust JID 1979

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

- **Total population (2022):** 326,740
- **Births (2022):** 9,466
- **Surviving infants (2022):** 9,308
- **Urban population (2020):** 24%

### Hepatitis B vaccine

- **HepB3 introduced nationwide:** 1989-1990
- **HepB birth dose introduced:** 1989-1990
- **Current schedule:** 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type:** DTwP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets:** pending
- **Verification started:** n.a.
- **Decision:** n.a.
- **Decision date:** n.a.

### Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>12-23 months</td>
<td>359</td>
<td>not reported</td>
<td>59%</td>
<td>63%</td>
<td>MICS; by 12 months 55% HepB3, 58% DTP3</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>12-23 months</td>
<td>303</td>
<td>not reported</td>
<td>55%</td>
<td>55%</td>
<td>DHS Survey; by 12 months 49% HepB3, 49% DTP3</td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>12-23 months</td>
<td>359</td>
<td>not reported</td>
<td>59%</td>
<td>63%</td>
<td>MICS; by 12 months 55% HepB3, 58% DTP3</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Emao or Nguna</td>
<td>12-18 months</td>
<td>Community based</td>
<td>112</td>
<td>17%</td>
<td>Maher Med J Aust 1991</td>
</tr>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>132</td>
<td>3.0%</td>
<td>Wilson Vaccine 2000</td>
</tr>
</tbody>
</table>

### Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

### Sources:
- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**VIET NAM**

### Demographics

- **Total population (2022)**: 98,186,856
- **Births (2022)**: 1,442,809
- **Surviving infants (2022)**: 1,423,035
- **Urban population (2020)**: 38%

### Hepatitis B vaccine

- **HepB3 introduced nationwide**: 1997
- **HepB birth dose introduced**: 2005
- **Current schedule**: 0, 2 months, 3 months, 4 months
- **HepB3 type**: DTbP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Neonatal deliveries

- **Total population**: 98,186,856
- **Births**: 1,442,809
- **Surviving infants**: 1,423,035
- **Urban population (2020)**: 38%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>National</td>
<td>12-24 months</td>
<td>457</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>555</td>
<td>not reported</td>
<td>34%</td>
<td>79%</td>
<td>MICS; 32% HepB3 and 76% DTP3 by 12 months</td>
</tr>
<tr>
<td>2002-2003</td>
<td>National</td>
<td>12-23 months</td>
<td>457</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2010-2011</td>
<td>National</td>
<td>12-23 months</td>
<td>759</td>
<td>not reported</td>
<td>56%</td>
<td>74%</td>
<td>MICS; 53% HepB3 and 73% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>24-35 months</td>
<td>641</td>
<td>71%</td>
<td>92%</td>
<td>93%</td>
<td>MICS; 71% HepB BD, 92% HepB3 and 93% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>12-23 months</td>
<td>790</td>
<td>78%</td>
<td>87%</td>
<td>89%</td>
<td>MICS; 78% HepB BD, 87% HepB3 and 89% DTP3 by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>2417</td>
<td>56%</td>
<td>98%</td>
<td>85%</td>
<td>WHO-UNICEF Joint Reporting Form (data for 2017)</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Thanh Hoa</td>
<td>9-18 months</td>
<td>Community based</td>
<td>536</td>
<td>12.5%</td>
<td>Hipgrave AJTMH 2003</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>3-4 years</td>
<td>Community based</td>
<td>3426</td>
<td>1.6% (1.25%-2.15%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>5-7 years</td>
<td>Community based</td>
<td>1738</td>
<td>2.2% (1.47%-3.14%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>8-11 years</td>
<td>Community based</td>
<td>1740</td>
<td>3.6% (2.80%-4.71%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
</tbody>
</table>

**Abbreviations**:
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- **Sources**:
  - Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
### Demographics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2022)</td>
<td>11,572</td>
</tr>
<tr>
<td>Births (2022)</td>
<td>135</td>
</tr>
<tr>
<td>Surviving infants (2022)</td>
<td>134</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>0%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- HepB3 introduced nationwide: Yes, introduction year unknown
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 2 months, 11 months
- HepB3 type: DTaP-Hib-HepB-IPV

### WHO verification

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Neonatal deliveries

![Graph showing neonatal deliveries](image)

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>7-12 years</td>
<td>442</td>
<td></td>
<td>not reported</td>
<td>94%</td>
<td>not reported</td>
<td>Data from national serosurvey</td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

![Graph showing vaccination coverage](image)

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD</th>
<th>HepB3</th>
<th>DTP3</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>7-12 years</td>
<td>442</td>
<td></td>
<td></td>
<td></td>
<td>Data from national serosurvey</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

![Graph showing hepatitis B serological surveys](image)

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>National</td>
<td>9-11 years</td>
<td>School-based</td>
<td>428</td>
<td>0.93%</td>
<td>Preliminary data</td>
</tr>
</tbody>
</table>

### Abbreviations
- DTP3: 3rd dose of Diptheria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization